TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05900778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: 2 weeks HABIT-ILE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional intervention
Description: 2 weeks usual intervention (waitlist group)
Study: NCT04581993

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Cereal - wheat soya blend with sugar
Description: Pregnant and lactating women will received Super Cereal during pregnancy and first six months of lactation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplement-medium quantity (LNS-MQ)
Description: Children will receive LNS during 6-23 months of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and behavior change communication (SBCC)
Description: SBCC will be provided to improve care-givers knowledge, attitudes and practices related to infant and young child feeding.
Study: NCT05377619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: prucalopride 2 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: buspirone 10 mg 1 hour before the challenge with intake of wine (200 ml) and a dinner

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 1 hour before the challenge with intake of wine (200 ml) and a dinner
Study: NCT05703581

Intervention type: PROCEDURE
Intervention: TRIANGLE operation
Description: dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)

Intervention type: PROCEDURE
Intervention: TRIANGLE operation
Description: dissection the region composed of common hepatic artery (CHA), superior mesenteric artery (SMA) and superior mesenteric vein (SMV)
Study: NCT06555484

Intervention type: DEVICE
Group type: OTHER
Intervention: Cross Over Assignment Supplemental Oxygen and Supplemental Air
Description: Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned).

Intervention type: DEVICE
Group type: OTHER
Intervention: Cross Over Assignment Supplemental Oxygen and Supplemental Air
Description: Subjects repeatedly complete memory tests, either first while breathing supplemental oxygen or first while breathing supplemental air (in an order randomly assigned).
Study: NCT06268938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Canal wall down tympanomastoidectomy
Description: Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canal wall down tympanomastoidectomy
Description: Mastoid cavity obliteration by in canal wall down tympanomastoidectomy tympanomastoidectomy in cholesteatoma surgery
Study: NCT05034601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB group
Description: A 21-gauge 100-mm needle will be inserted into the fascial layer beneath the iliocostalis, longissimus, and spinalis muscles. A bolus of 0.25% ropivacaine 0.5 ml/kg will be injected into the fascial layer. Contralateral ESPB will be performed similarly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPVB group
Description: A 21-gauge 100-mm insulated needle will be inserted into the paravertebral space via an in-plane parasagittal approach. After perforating the costotransverse ligament, 0.25% ropivacaine 0.5 ml/kg will be injected. Anterior movement of the pleura indicated the appropriate spread of the local anesthetics in the paravertebral space. The process will be repeated on the contralateral side.
Study: NCT05566171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Activia Probiotic Yogurt
Description: Activia probiotic Yogurt will be consumed by participants in this group
Study: NCT06418659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-801
Description: CD-801 will be administered intravenously for the treatment of HCC. The dosing regimen is planned for a second dose 14 ± 3 days post-initial treatment, followed by subsequent treatments every 28 ± 7 days, with adjustments made based on patient tolerance and therapeutic response.
Study: NCT06124391

Intervention type: OTHER
Intervention: Long-term follow-up
Description: Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.

Intervention type: OTHER
Intervention: Long-term follow-up
Description: Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.

Intervention type: OTHER
Intervention: Long-term follow-up
Description: Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.

Intervention type: OTHER
Intervention: Long-term follow-up
Description: Participants diagnosed with PCOS were not subjected to any specific intervention post-diagnosis. Instead, they were followed up after 6.5 years to assess various outcomes related to PCOS and associated conditions.
Study: NCT05888753

Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Scheduled adrenal surgery

Intervention type: PROCEDURE
Intervention: Adrenalectomy
Description: Scheduled adrenal surgery
Study: NCT06238076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Universal surgical device FIBUMAND
Description: This device is made of biocompatible resin for type IIa medical devices with a 3D printer.
Study: NCT05583396

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acute exercise
Description: The measurement will be repeated within one to seven days.
Study: NCT05058924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic low molecular weight heparin
Description: Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin and low-dose aspirin
Description: Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.
Study: NCT04649775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirFLO2
Description: Mask device
Study: NCT06330922

Intervention type: OTHER
Intervention: Cardiorespiratory fitness training
Description: Cardiorespiratory fitness training will be performed two times a week for one hour in small groups (4-5 people). The training will be conducted outdoors at track and field facilities with at least two coaches.
Study: NCT05464004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii balance board
Description: Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nintendo Wii balance board
Description: Experimental group was given Nintendo Wii balance board therapy in combination with conventional physical therapy for 16 sessions/8 weeks~Control group was conventional physical therapy which include stretching of the hamstrings, quadriceps and calf muscles. strengthening of the lower limb. Balance exercises include walk in parallel bar
Study: NCT05312671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 20 mL (1200 mg) on Day 1, once every 3 weeks for up to 20 cycles (each cycle = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV on Day 1, once every 3 weeks for first 4 cycles (each cycle = 21 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m2 IV on Days 1 - 3 every cycle for the first 4 cycles (each cycle = 21 days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Cystectomy should be performed within 42 days after completion of last administered study therapy of induction phase (first 4 cycles of chemotherapy).
Study: NCT05374265

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Magnetic Resonance Scan
Description: Patients will receive a baseline CMR scan to detect viability within 7 days of index admission

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Magnetic Resonance Scan
Description: Patients will receive a baseline CMR scan to detect viability within 7 days of index admission
Study: NCT05625035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lianhua Qingwen capsules
Description: Lianhua Qingwen capsules: 4 capsules once, three times daily
Study: NCT05640570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The individualized Jade Wind-Barrier Herbal Tea Bag
Description: The individualized Jade Wind Barrier Herbal Tea Bag is composed of Astragali Radix (Zhi Huangqi) 4g, Saposhnikoviae Radix (Fangfeng) 2g, Atractylodes macrocephala Koidz (Baizhu) 2g, Nelumbinis Folium (Heye) 1g, Chrysanthemum morifolium Ramat (Juhua) 1g.
Study: NCT04865432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVB treatment
Description: 5 weeks of UVB titration to determine individual's UVB sensitivity followed by 4 weeks of UVB exposure intervention
Study: NCT04820790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile applications
Description: Monitoring of patients with home oxygen through a mobile application
Study: NCT05685290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pushing with saline technique
Description: Peripheral venous catheter placement by pushing with saline technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional method
Description: Peripheral venous catheter placement with the traditional method by nurses in the clinic routinely.
Study: NCT06198816

Intervention type: OTHER
Intervention: ultrasound accelerated thrombolysis and venoplasty
Description: IDOLO Study investigate clinical efficacy on ultrasound accelerated thrombolysis and venoplasty in patients with post-thrombotic syndrome secondary to chronical femoro-popliteal vein occlusion for previous deep vein Thrombosis (DVT).
Study: NCT05469464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orismilast modified release tablets
Description: Orismilast modified release is a next generation PDE4 inhibitor with high selectivity for the PD4 subtypes linked to inflammation.~Other Names:~* UNI50001~* LEO32731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching tablets
Study: NCT06643936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E3 Multidisciplinary Team
Description: The E3 Multidisciplinary team is composed of a remote pharmacist, social worker, community health worker, and dietician working together to overcome barriers to diabetes control via behavioral change, medication adherence and titration, diet and lifestyle education and resource referrals for social needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: E3 Self-Guided Type 2 Diabetes Education
Description: Patients will receive timed, mailed educational materials on diabetes monitoring, diet and lifestyle modifications to supplement usual clinic based type 2 diabetes care with their primary care doctor. A registered nurse will ensure patients have glucometers and supplies, and remind patients to obtain A1C readings at 3 months and 6 months via phone call.
Study: NCT05002049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Teenagers with leadership skills from intervention schools (called ambassadors) and stakeholders will participate in focus groups to gain insights on the barriers and facilitators for healthy lifestyles of teenagers, and how science could help address these. Building on the information of the focus groups, ambassadors, stakeholders and other peers will participate in a collaborative competition event where the SEEDS intervention(s) will be designed. The intervention(s) will be implemented at intervention high-schools during 6 months. Outcomes in health behaviours and science literacy will be assessed by validated questionnaires at the start and end of the project.
Study: NCT04958655

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tetris Task
Description: a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tetris Task
Description: a visual task where participants are asked to play 'tetris' i.e. attend to and manipulate shapes and positions on screen

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate a specific future mental image to reduce cue-induced craving for alcohol
Study: NCT06656702

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybin
Description: Psilocybin Trihydrate. Participants will complete an 8-week course of study treatment including two psilocybin sessions (15 mg in week 4 and 15 or 25 mg in week 6), with follow-up assessments 1, 3, and 6 months after the final psilocybin session.
Study: NCT06401551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO Pro IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO Pro IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining comparable distance visual acuity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPO IOL
Description: Intraocular lens (IOL) implanted in the eye for the visual correction of aphakia in adult patients with less than 1 diopter of preexisting corneal astigmatism in whom a cataractous lens has been removed. The IOL is intended to mitigate the effects of presbyopia on intermediate and near visual acuity while maintaining distance visual acuity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Extraction of the cataractous lens by phacoemulsification, followed by implantation of the IOL.
Study: NCT05623501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: Dose-escalation and lysine preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: Dose-escalation and lysine preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: Dose-escalation and lysine preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydromyricetin
Description: Dose-escalation and lysine preparation
Study: NCT05973825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leucapheresis
Description: leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure
Study: NCT06144047

Intervention type: DEVICE
Group type: OTHER
Intervention: EEG SubQ subcutaneous EEG device
Description: 2-channel subcutaneous EEG device
Study: NCT05720923

Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function

Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function

Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function

Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function
Study: NCT05020210

Intervention type: DRUG
Intervention: Sivelestat sodium
Description: Patients were treated with Sivelestat Sodium within 72 hours of the diagnosis of ARDS.
Study: NCT06527417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro Trac Myo Plus Pro
Description: Electrical stimulation parameters; stimuli were monophasic, rectangular, stimulus duration 300 µs, frequency 25 Hertz, amplitude was increased up to a maximum of 100 milliampere until contraction was seen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk eccentric exercises
Description: The control group performed back eccentric exercises for 4 weeks, 3 times a week, 3 times in each session
Study: NCT06546852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Patient education will be provide
Study: NCT05720923

Intervention type: DEVICE
Intervention: Analysis with Ergometer
Description: The analysis with the ergometer aims at assessing neuromuscular function
Study: NCT05603416

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Perilla frutescens extract
Description: oral dissolvable powder - dosage 300mg
Study: NCT05984914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSAI
Description: The 8 sessions included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention, introduction to the Pythagorean Self-Awareness Intervention, instructions for the implementation of the technique, analysis of the Golden Verses,and their connection with lifestyle medicine as well as active involvement of the participants with group conversation and sharing of experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One day seminar
Description: The one day seminar included biofeedback training in diaphragmatic breathing, information about distress, its symptoms, ways to manage stress through lifestyle modifications (physical activity, principals of Mediterranean diet without alcohol consumption, sleep hygiene, diaphragmatic breathing, conflict avoidance) \& instructions for lymphedema prevention.
Study: NCT05846555

Intervention type: PROCEDURE
Intervention: urologic surgery
Description: surgery

Intervention type: PROCEDURE
Intervention: urologic surgery
Description: surgery
Study: NCT05603416

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dissolvable powder - dosage 300mg no active ingredient
Study: NCT01297868

Intervention type: OTHER
Intervention: exercise
Study: NCT06483035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Visual Stimulation (IVS)
Description: The IVS system initially makes a video-recording of the intact body part (arm or leg) executing a set of specific movements. These video recordings will be digitally reversed and projected onto a large screen in front of the patient. On the screen, the patient will monitor an intact, life-like extremity in place of the amputated extremity. This digital extremity will then execute the recorded movements in a pre-planned manner. Simultaneously, the patient will follow the digital virtual limb moving on the screen with his/hers amputated arm/leg, which is hidden below the screen. Hence, IVS therapy comprises elements of both movement perception, motor planning, motor execution and visual feedback of two intact limbs moving which are distinctive from classical Mirror-Therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: After allocation to UC, the participants continue with their normal treatment as prescribed by their medical doctor. All control participants are offered to complete IVS treatment after the end of the study period. The participants in the control group will therefore be placed on a fictitious waiting list during the study period.
Study: NCT05129072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Toric LD213001 lens in SKUs +6D, +3D, 0D, -3D, -6D, and -9D
Description: kalifilcon A Daily Disposable Toric LD213001 lens
Study: NCT06361823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Giving Semaglutide via subcutaneous injections on a weekly basis for a duration of 3 months. The dosage is 0.25 mg for the initial month, then upped to 0.5 mg for patients who could handle it in the second month, and eventually escalated to 1.0 mg for patients who continued to tolerate it in the third month.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low calorie diet
Description: Low calorie diet (max 1200 kcal/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Low calorie diet (max 1200 kcal/day)